If Wall Street was looking for a biotech deal that would validate the sector's lofty valuation and provide more fuel for the recent rally, Monday's merger of Idec Pharmaceuticals ( IDPH) and Biogen ( BGEN) probably isn't it.That's not to say the $6.5 billion
Editor's Note: Interested in learning more about biotech? Attend an interactive chat Wednesday, June 25 with RealMoney columnist Adam Feuerstein to learn the five things you need to know before buying a biotech stock -- and also to ask questions of Adam. Tune in to chat about this hot sector! Click here for more information and to sign up.